Subjective cognitive decline domain improves accuracy of plasma Aβ_(42)/Aβ_(40)for preclinical Alzheimer’s disease diagnosis:The SILCODE study  

作　　者：Mingkai Zhang Xiaoni Wang Weina Zhao Yuxia Li Chao Ying Jiehui Jiang Yanning Cai Jie Lu Ying Han 

机构地区：[1]Department of Neurology,Xuanwu Hospital of Capital Medical University,Beijing 100053,China [2]Department of Neurology,Sir Run Run Shaw Hospital,Affiliated with School of Medicine,Zhejiang University,Hangzhou,Zhejiang 310016,China [3]Department of Neurology,Hongqi Hospital Affiliated to Mudanjiang Medical University,Mudanjiang,Heilongjiang 157011,China [4]Heilongjiang Key Laboratory of Ischemic Stroke Prevention and Treatment,Mudanjiang,Heilongjiang 157011,China [5]Department of Neurology,Tangshan Central Hospital,Tangshan,Hebei 063000,China [6]Department of Neurobiology,Xuanwu Hospital of Capital Medical University,Key Laboratory for Neurodegenerative Diseases of the Ministry of Education,Beijing 100053,China [7]Institute for Advanced Communication and Data Science,Shanghai University,Shanghai 200444,China [8]Department of Radiology and Nuclear Medicine,Xuanwu Hospital,Capital Medical University,Beijing 100053,China [9]Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics,Beijing 100053,China [10]Key Laboratory of Neurodegenerative Diseases,Ministry of Education,Beijing 100053,China [11]School of Biomedical Engineering,Hainan University,Haikou,Hainan 570228,China [12]Center of Alzheimer’s Disease,Beijing Institute for Brain Disorders,Beijing 100053,China [13]National Clinical Research Center for Geriatric Disorders,Beijing 100053,China [14]Institute of Biomedical Engineering,Shenzhen Bay Laboratory,Shenzhen,Guangdong 518132,China

出　　处：《Chinese Medical Journal》2024年第9期1127-1129,共3页中华医学杂志（英文版）

基　　金：supported by grants from the National Natural Science Foundation of China(Nos.82020108013 and 82001773);National Key Research and Development Program of China(No.2022YFC24069004);Beijing Brain Initiative from Beijing Municipal Science&Technology Commission(No.Z201100005520018);STI2030-Major Projects(No.2022ZD0211800)

摘　　要：To the Editor:Accumulating evidence has shown that the preclinical stage of Alzheimer’s disease(AD)(i.e.,asymptomatic amyloidosis)lasts for decades before the onset of cognitive symptoms,providing a large window for early intervention.Amyloid pathology,the earliest pathological change associated with AD,can be detected in vivo with cerebrospinal fluid(CSF)analysis or positron emission tomography(PET),and its presence is necessary for the diagnosis of preclinical AD(pre-AD).However,both PET scans and CSF analyses are expensive,hampering their use in large-scale screening.Thus,blood-based biomarkers are desirable alternatives,as they are cost-effective and not invasive.

关 键 词：diagnosis clinical ALZHEIMER 

分 类 号：R749.16[医药卫生—神经病学与精神病学]